{
    "code": "52028537",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028537",
    "time": "2024-04-11 20:00:56",
    "許可證字號": "衛部藥輸字第028537號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "117\/09\/11",
    "發證\/登錄日期": "112\/09\/11",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202853703",
    "中文品名": "捷抑炎口服液1毫克\/毫升",
    "英文品名": "Xeljanz Oral Solution 1 mg\/mL",
    "適應症": "多關節型兒童特發性關節炎：\r\n適用於治療2歲以上病人的活動性多關節型兒童特發性關節炎(pcJIA)，病人先前需對methotrexate或其他疾病緩解型抗風溼藥物(DMARDs)無法產生適當治療反應或無法耐受。\r\n使用限制：不建議XELJANZ口服液與生物性的疾病緩解型抗風濕藥物(DMARDs)，或與強效免疫抑制劑(如azathioprine與cyclosporine)合併使用。",
    "劑型": "189口服液劑",
    "包裝": "(含壓入式藥瓶轉接頭及口服給藥注射器) 4000毫升以下塑膠瓶裝(HDPE)",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新療效(新適應症); 新劑型;",
    "監視期限": "117\/09\/11",
    "主成分略述": "Tofacitinib citrate",
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "輝瑞大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "製造廠名稱": "PHARMACIA &amp; UPJOHN COMPANY LLC",
            "製造廠廠址": "7000 Portage Road, Kalamazoo, MI, 49001, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "久裕企業股份有限公司(委託包裝)",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓、3樓、1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200080610",
            "成分名稱": "Tofacitinib citrate",
            "含量描述": "(Equivalent to 1 MG tofacitinib)",
            "含量": "1.6200000000",
            "單位": "MG"
        }
    ]
}